company background image
IMCR

Immunocore Holdings NasdaqGS:IMCR Stock Report

Last Price

US$62.81

Market Cap

US$3.0b

7D

-0.7%

1Y

89.9%

Updated

01 Dec, 2022

Data

Company Financials +
IMCR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

IMCR Stock Overview

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.

Immunocore Holdings plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Immunocore Holdings
Historical stock prices
Current Share PriceUS$62.81
52 Week HighUS$69.06
52 Week LowUS$18.43
Beta0
1 Month Change9.92%
3 Month Change21.02%
1 Year Change89.87%
3 Year Changen/a
5 Year Changen/a
Change since IPO45.39%

Recent News & Updates

Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically

Nov 16
Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically

Immunocore: Attractive Commercial-Stage Biopharma

Oct 05

Recent updates

Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically

Nov 16
Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically

Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)

Aug 12
Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)

Analysts Are Updating Their Immunocore Holdings plc (NASDAQ:IMCR) Estimates After Its Second-Quarter Results

Aug 15
Analysts Are Updating Their Immunocore Holdings plc (NASDAQ:IMCR) Estimates After Its Second-Quarter Results

Industry Analysts Just Upgraded Their Immunocore Holdings plc (NASDAQ:IMCR) Revenue Forecasts By 12%

May 20
Industry Analysts Just Upgraded Their Immunocore Holdings plc (NASDAQ:IMCR) Revenue Forecasts By 12%

Shareholder Returns

IMCRUS BiotechsUS Market
7D-0.7%2.3%1.5%
1Y89.9%-10.2%-14.8%

Return vs Industry: IMCR exceeded the US Biotechs industry which returned -15.2% over the past year.

Return vs Market: IMCR exceeded the US Market which returned -18.9% over the past year.

Price Volatility

Is IMCR's price volatile compared to industry and market?
IMCR volatility
IMCR Average Weekly Movement10.3%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: IMCR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: IMCR's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999324Bahija Jallalhttps://www.immunocore.com

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers.

Immunocore Holdings plc Fundamentals Summary

How do Immunocore Holdings's earnings and revenue compare to its market cap?
IMCR fundamental statistics
Market CapUS$3.01b
Earnings (TTM)-US$66.12m
Revenue (TTM)US$122.04m

24.7x

P/S Ratio

-45.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMCR income statement (TTM)
RevenueUK£102.27m
Cost of RevenueUK£82.45m
Gross ProfitUK£19.82m
Other ExpensesUK£75.23m
Earnings-UK£55.41m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.16
Gross Margin19.38%
Net Profit Margin-54.18%
Debt/Equity Ratio15.5%

How did IMCR perform over the long term?

See historical performance and comparison